{
      "ptx_code": "PTX026",
      "chem_name": "Chlorpyrifos",
      "casrn": "2921-88-2",
      "dtxsid": "DTXSID4020458",
      "smiles": "CCOP(=S)(OCC)OC1=NC(Cl)=C(Cl)C=C1Cl",
      "inchikey": "SBPBAQFWLVIOKP-UHFFFAOYSA-N",
      "label": "PTX026 | Chlorpyrifos",
      "drugbank_id": "",
      "use_class": "Pesticide",
      "tox_class": "Neurotoxicity; Genotoxicity; Immunotoxicity",
      "chem_name_user": "Chlorpyrifos",
      "mw_g_mol": "350.57",
      "solubility_h2o_mol_liter": "2.36e-06",
      "source_solubility_h2o": "COMPTOX",
      "henry_coefficient_atm_m3_mol": "2.92e-06",
      "source_henry": "COMPTOX (Opera)",
      "log_kaw_kh_rt": "3.92",
      "source_kaw": "LSER eq 1",
      "pka_acid": "",
      "pka_base": "",
      "source_pka": "UFZ; Sirius T3",
      "log_kow_liter_liter": "4.96",
      "source_kow": "experimental, Sangster et al. (1994)",
      "log_dlipw_ph74_liter_liter": "5.13",
      "source_dlipw": "Kow-QSAR (mw=1)",
      "freely_dissolved_fraction": "0.03",
      "density_kg_liter": "1.49",
      "source_density": "COMPTOX",
      "average_mass": "350.57",
      "boiling_point": "160.0 \u00b0C",
      "source_boiling_point": "NIOSH",
      "melting_point": "41.5 \u00b0C",
      "source_melting_point": "Jean-Claude Bradley Open Melting Point Dataset",
      "vapor_pressure": "2.02488E-5 mmHg",
      "source_vapor_pressure": "PhysPropNCCT",
      "baseline_drerio": "1.39",
      "baseline_dmagna": "2.15",
      "baseline_celegans": "4.82",
      "baseline_xlaevis": "5.72",
      "baseline_dmelanogaster": "17.86",
      "baseline_cells": "5.93e-06",
      "baseline_cells_generic_micromole_liter_free_ec10": "1.93e-07",
      "moa_drugbank": "",
      "protein_binding": "",
      "moa_t3db": "Chlorpyrifos and its bioactivation product, chlorpyrifos oxon, and inhibit neural acetylcholinesterase by forming a stable covalent bond at the active site. The result of this acetylcholinesterase inhibition is cholinergic overstimulation of the central nervous system. (L268); Chlorpyrifos oxon binds to muscarinic receptors, altering the receptors signal transduction, which affects cellular signalling and disrupts neurological function. (A163); Chlorpyrifos oxon binds albumin and may generate an antibody response. (A164); Chlorpyrifos is an irreversible non-competitive inhibitor of cytochrome P-450 3A4. (A166); Chlorpyrifos inhibits neuropathy target esterase, producing ataxia. (A167); Chlorpyrifos oxon inhibits cannabinoid receptor 1. (A168); Chlorpyrifos inhibits an endogenous signaling modulator, fatty acid amide hydrolase, producing secondary neurotoxicity. (A217); This organochloride inhibits Na+/K+ ATPase and Ca2+ and Mg2+ ATPase, which are essential for the transport of calcium across membranes. This results in the accumulation of intracellular free calcium ions, which promotes release of neurotransmitters from storage vesicles, the subsequent depolarization of adjacent neurons, and the propagation of stimuli throughout the central nervous system. (T10); This organochloride antagonizes the action of the neurotransmitter gamma-aminobutyric acid (GABA) acting at the GABA-A receptors, effectively blocking the GABA-induced uptake of chloride ions and causing hyperexcitability of the central nervous system. (T10); Causes endocrine disruption in humans by binding to and inhibiting the estrogen receptor. (A590)",
      "aop": [
            {
                  "AOP_id": 6,
                  "AOP_name": "Antagonist binding to PPAR\u03b1 leading to body-weight loss "
            },
            {
                  "AOP_id": 18,
                  "AOP_name": "PPAR\u03b1 activation in utero leading to impaired fertility in males "
            },
            {
                  "AOP_id": 19,
                  "AOP_name": "Androgen receptor antagonism leading to adverse effects in the male foetus (mammals) "
            },
            {
                  "AOP_id": 34,
                  "AOP_name": "LXR activation leading to hepatic steatosis "
            },
            {
                  "AOP_id": 57,
                  "AOP_name": "AhR activation leading to hepatic steatosis "
            },
            {
                  "AOP_id": 58,
                  "AOP_name": "NR1I3 (CAR) suppression leading to hepatic steatosis "
            },
            {
                  "AOP_id": 61,
                  "AOP_name": "NFE2L2/FXR activation leading to hepatic steatosis "
            },
            {
                  "AOP_id": 72,
                  "AOP_name": "Epigenetic modification of PPARG leading to adipogenesis "
            },
            {
                  "AOP_id": 97,
                  "AOP_name": "5-hydroxytryptamine transporter (5-HTT; SERT) inhibition leading to population decline "
            },
            {
                  "AOP_id": 98,
                  "AOP_name": "5-hydroxytryptamine transporter (5-HTT; SERT) inhibition leading to decreased shelter seeking and increased predation "
            },
            {
                  "AOP_id": 123,
                  "AOP_name": "Unknown MIE leading to reproductive dysfunction via increased HIF-1alpha transcription "
            },
            {
                  "AOP_id": 131,
                  "AOP_name": "Aryl hydrocarbon receptor activation leading to uroporphyria "
            },
            {
                  "AOP_id": 148,
                  "AOP_name": "EGFR Activation Leading to Decreased Lung Function "
            },
            {
                  "AOP_id": 195,
                  "AOP_name": "5-hydroxytryptamine transporter (5-HTT) inhibition leading to population increase "
            },
            {
                  "AOP_id": 203,
                  "AOP_name": "5-hydroxytryptamine transporter inhibition leading to decreased reproductive success and population decline "
            },
            {
                  "AOP_id": 204,
                  "AOP_name": "5-hydroxytryptamine transporter inhibition leading to increased reproductive success and population increase "
            }
      ],
      "targets": [
            "Acetylcholinesterase",
            "Aryl hydrocarbon receptor",
            "Calcium-transporting ATPase type 2C member 1",
            "Calcium-transporting ATPase type 2C member 2",
            "Cannabinoid receptor 1",
            "Cytochrome P450 3A4",
            "Estrogen receptor alpha",
            "Estrogen receptor beta",
            "Fatty-acid amide hydrolase 1",
            "Fatty-acid amide hydrolase 2",
            "Gamma-aminobutyric acid receptor subunit alpha-1",
            "Gamma-aminobutyric acid receptor subunit alpha-2",
            "Gamma-aminobutyric acid receptor subunit alpha-3",
            "Gamma-aminobutyric acid receptor subunit alpha-4",
            "Gamma-aminobutyric acid receptor subunit alpha-5",
            "Gamma-aminobutyric acid receptor subunit alpha-6",
            "Gamma-aminobutyric acid receptor subunit beta-1",
            "Gamma-aminobutyric acid receptor subunit beta-2",
            "Gamma-aminobutyric acid receptor subunit beta-3",
            "Gamma-aminobutyric acid receptor subunit delta",
            "Gamma-aminobutyric acid receptor subunit epsilon",
            "Gamma-aminobutyric acid receptor subunit gamma-1",
            "Gamma-aminobutyric acid receptor subunit gamma-2",
            "Gamma-aminobutyric acid receptor subunit gamma-3",
            "Gamma-aminobutyric acid receptor subunit pi",
            "Gamma-aminobutyric acid receptor subunit rho-1",
            "Gamma-aminobutyric acid receptor subunit rho-2",
            "Gamma-aminobutyric acid receptor subunit rho-3",
            "Gamma-aminobutyric acid receptor subunit theta",
            "Multidrug resistance protein 1",
            "Muscarinic acetylcholine receptor M1",
            "Muscarinic acetylcholine receptor M2",
            "Muscarinic acetylcholine receptor M3",
            "Muscarinic acetylcholine receptor M4",
            "Muscarinic acetylcholine receptor M5",
            "Neuropathy target esterase",
            "Nuclear receptor subfamily 1 group I member 2",
            "Nuclear receptor subfamily 1 group I member 3",
            "Peroxisome proliferator-activated receptor delta",
            "Plasma membrane calcium-transporting ATPase 1",
            "Plasma membrane calcium-transporting ATPase 2",
            "Plasma membrane calcium-transporting ATPase 3",
            "Plasma membrane calcium-transporting ATPase 4",
            "Sarcoplasmic/endoplasmic reticulum calcium ATPase 1",
            "Sarcoplasmic/endoplasmic reticulum calcium ATPase 2",
            "Sarcoplasmic/endoplasmic reticulum calcium ATPase 3",
            "Serum albumin",
            "Sodium/potassium-transporting ATPase subunit alpha-1",
            "Sodium/potassium-transporting ATPase subunit alpha-2",
            "Sodium/potassium-transporting ATPase subunit alpha-3",
            "Sodium/potassium-transporting ATPase subunit alpha-4",
            "Sodium/potassium-transporting ATPase subunit beta-1",
            "Sodium/potassium-transporting ATPase subunit beta-2",
            "Sodium/potassium-transporting ATPase subunit beta-3",
            "Sodium/potassium-transporting ATPase subunit gamma"
      ]
}